What is HW241045 studying for healthy volunteers?

HW241045 is being studied to understand its safety, tolerability, and how it is processed in the body after a single oral dose in healthy adults. This trial aims to provide important information on how the drug behaves and any side effects. The study is sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Who may be eligible for this healthy volunteer clinical trial?

Adults aged 18 to 55 years who are healthy and meet weight and body mass index requirements may be eligible. Both males and females can participate, and they must consent to the study. People with certain health conditions, recent surgeries, or drug allergies may not qualify. Please review eligibility criteria for more details.

Is there any cost to participate in this healthy volunteer clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. Participants may need to cover their own travel or personal expenses, which are not guaranteed to be reimbursed.

Actively Recruiting

Phase 1

Age: 18Years - 55Years

All Genders

Healthy Volunteers

ID07448194

Phase Ia Study Evaluating Safety, Tolerability, and Pharmacokinetics of HW241045 Tablets as a Single Dose in Healthy Adults

Led by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Updated on 2026-03-04

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying HW241045 in a Phase Ia clinical trial to evaluate its safety, tolerability, and how it is processed in the body after a single dose. This randomized, double-blind, placebo-controlled study involves healthy adult volunteers aged 18 to 55 years to better understand the effects of this drug compared to a placebo. Participants will receive a single oral dose of either HW241045 or a placebo. The study is designed with two groups one receiving the experimental drug and the other receiving placebo, both under blinded conditions to ensure unbiased results. The trial is conducted at a single center and uses a quadruple masking approach. During the study, participants will be closely monitored for any treatment-emergent adverse events within 48 hours after dosing. Assessments include safety checks, tolerability evaluations, and pharmacokinetic measurements. Participants health will be carefully observed during this period to understand the drugs effects and side effects. The total duration of participation is determined by these assessments and monitoring schedules.

CONDITIONS

Brief Title

A Phase Ia Clinical Trial of HW241045

Who Can Participate

Age: 18Years - 55Years

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Subjects fully informed about the trial and voluntarily sign consent
Healthy male and female subjects aged 18 to 55 years
Female subjects must weigh at least 45 kg and male subjects at least 50 kg
Body mass index (BMI) between 19 and 26 kg/m²

You will not qualify if you...

History or current severe diseases affecting circulatory, endocrine, nervous, digestive, respiratory, hematological, immune, mental, or metabolic systems
Severe trauma or major surgery within 3 months before screening or planned surgery during the trial or within two weeks after
History of gastrointestinal, liver, or kidney diseases affecting drug absorption or metabolism
Clinically significant abnormal screening test results
History of drug or food allergy, allergic disorders, or sensitivity to any component of the study drug
Difficult venous blood collection or inability to tolerate intensive blood sampling
Judged unsuitable for the study by the investigator due to other reasons

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here